Is CytomX Therapeutics Stock a Good Investment?
CytomX Therapeutics Investment Advice | CTMX |
- Examine CytomX Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research CytomX Therapeutics' leadership team and their track record. Good management can help CytomX Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact CytomX Therapeutics' business and its evolving consumer preferences.
- Compare CytomX Therapeutics' performance and market position to its competitors. Analyze how CytomX Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if CytomX Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about CytomX Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in CytomX Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if CytomX Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine CytomX Therapeutics Stock
Researching CytomX Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 58.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years.
To determine if CytomX Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CytomX Therapeutics' research are outlined below:
| CytomX Therapeutics generated a negative expected return over the last 90 days | |
| CytomX Therapeutics has some characteristics of a very speculative penny stock | |
| CytomX Therapeutics has high historical volatility and very poor performance | |
| CytomX Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| CytomX Therapeutics currently holds about 194.29 M in cash with (86.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: SRPT Nosedives 27 percent on Patient Death Following DMD Therapy Infusion |
CytomX Therapeutics Quarterly Accounts Payable |
|
CytomX Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CytomX Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CytomX Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact CytomX Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises CytomX Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-11 | 2023-12-31 | -0.03 | 0.01 | 0.04 | 133 | ||
2022-11-08 | 2022-09-30 | -0.31 | -0.35 | -0.04 | 12 | ||
2021-11-04 | 2021-09-30 | -0.31 | -0.35 | -0.04 | 12 | ||
2016-11-03 | 2016-09-30 | -0.35 | -0.4 | -0.05 | 14 | ||
2016-03-07 | 2015-12-31 | -0.34 | -0.39 | -0.05 | 14 | ||
2024-08-08 | 2024-06-30 | -0.14 | -0.08 | 0.06 | 42 | ||
2023-05-09 | 2023-03-31 | -0.11 | -0.05 | 0.06 | 54 | ||
2019-08-07 | 2019-06-30 | -0.57 | -0.64 | -0.07 | 12 |
Know CytomX Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CytomX Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CytomX Therapeutics backward and forwards among themselves. CytomX Therapeutics' institutional investor refers to the entity that pools money to purchase CytomX Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Congress Park Capital Llc | 2024-12-31 | 964.6 K | Geode Capital Management, Llc | 2024-12-31 | 815.6 K | Jpmorgan Chase & Co | 2024-12-31 | 811.6 K | Assenagon Asset Management Sa | 2024-12-31 | 599.9 K | Ubs Group Ag | 2024-12-31 | 508.6 K | Sei Investments Co | 2024-12-31 | 487.9 K | Altium Capital Management, Lp | 2024-12-31 | 467.5 K | Formidable Asset Management Llc | 2024-12-31 | 382.5 K | Tidal Investments Llc. | 2024-12-31 | 382.5 K | Tang Capital Management Llc | 2024-12-31 | 7.3 M | Bvf Inc | 2024-12-31 | 5.2 M |
CytomX Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 53.41 M.Market Cap |
|
CytomX Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.27 | 0.28 | |
| Return On Capital Employed | 0.72 | 0.76 | |
| Return On Assets | 0.26 | 0.28 | |
| Return On Equity | (69.89) | (66.39) |
Determining CytomX Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if CytomX Therapeutics is a good buy. For example, gross profit margin measures CytomX Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CytomX Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in CytomX Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CytomX Therapeutics. Check CytomX Therapeutics' Beneish M Score to see the likelihood of CytomX Therapeutics' management manipulating its earnings.
Evaluate CytomX Therapeutics' management efficiency
CytomX Therapeutics has return on total asset (ROA) of 0.0969 % which means that it generated a profit of $0.0969 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (54.7503) %, meaning that it created substantial loss on money invested by shareholders. CytomX Therapeutics' management efficiency ratios could be used to measure how well CytomX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, CytomX Therapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.76 in 2025, despite the fact that Return On Equity is likely to grow to (66.39). At this time, CytomX Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.1 M in 2025, whereas Total Assets are likely to drop slightly above 114.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.01) | (0.01) | |
| Tangible Book Value Per Share | (0.02) | (0.02) | |
| Enterprise Value Over EBITDA | 2.33 | 2.45 | |
| Price Book Value Ratio | (190.73) | (181.19) | |
| Enterprise Value Multiple | 2.33 | 2.45 | |
| Price Fair Value | (190.73) | (181.19) | |
| Enterprise Value | 58.3 M | 55.4 M |
CytomX Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 1.043 |
Basic technical analysis of CytomX Stock
As of the 24th of March, CytomX Therapeutics shows the Mean Deviation of 3.6, risk adjusted performance of (0.12), and Standard Deviation of 4.6. CytomX Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.CytomX Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CytomX Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on CytomX Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CytomX Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CytomX Therapeutics' Outstanding Corporate Bonds
CytomX Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CytomX Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CytomX bonds can be classified according to their maturity, which is the date when CytomX Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand CytomX Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing CytomX Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 3.6 | |||
| Coefficient Of Variation | (699.21) | |||
| Standard Deviation | 4.6 | |||
| Variance | 21.17 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.32) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 17.13 | |||
| Value At Risk | (7.45) | |||
| Potential Upside | 7.32 | |||
| Skewness | 0.415 | |||
| Kurtosis | 0.2287 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 3.6 | |||
| Coefficient Of Variation | (699.21) | |||
| Standard Deviation | 4.6 | |||
| Variance | 21.17 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.32) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 17.13 | |||
| Value At Risk | (7.45) | |||
| Potential Upside | 7.32 | |||
| Skewness | 0.415 | |||
| Kurtosis | 0.2287 |
Consider CytomX Therapeutics' intraday indicators
CytomX Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CytomX Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 30901.5 | |||
| Daily Balance Of Power | (0.01) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.67 | |||
| Day Typical Price | 0.67 | |||
| Price Action Indicator | 0.0047 | |||
| Period Momentum Indicator | (0.0002) |
CytomX Stock media impact
Far too much social signal, news, headlines, and media speculation about CytomX Therapeutics that are available to investors today. That information is available publicly through CytomX media outlets and privately through word of mouth or via CytomX internal channels. However, regardless of the origin, that massive amount of CytomX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CytomX Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CytomX Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CytomX Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CytomX Therapeutics alpha.
CytomX Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards CytomX Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
CytomX Therapeutics Corporate Management
| JD Rowland | General VP | Profile | |
| MBA BS | Head VP | Profile | |
| Danielle OlanderMoghadassian | Senior Officer | Profile | |
| YuWaye MD | Senior Officer | Profile | |
| Christopher Ogden | Principal Accounting | Profile |
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.